The Biostatistics Core of the proposed Johns Hopkins SPORE in lymphoma is designed to: 1) Provide biostatistical consultation and support to all projects in the program, by assisting in the design, collection, visualization, analysis, quantitative modeling, interpretation and publication of the data arising in the course of program activities. 2) Provide consultation for the design and analysis of clinical trials and other cohort studies to all the projects in the program by working with the Clinical Trials Core. 3) Provide the infrastructural support, programming, and computer maintenance necessary to biostatistical activities within the program. The Core will have an integral role in the scientific development, execution, and analysis of all projects in the SPORE, including the clinical trials. Core investigators have extensive and complementary experiences in quantitative methods for biomedical applications, including both clinical and basic science studies. They are committed to taking a direct interest in the substantive issues being investigated; to participating in regular project and program meetings, and to providing rigorous and innovative input on all quantitative matters arising in the projects. By contributing to multiple projects, they will also be in a position to promote interdisciplinary interactions among projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA096888-01
Application #
6686632
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-09-20
Project End
2007-06-30
Budget Start
Budget End
Support Year
1
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Jacene, Heather; Crandall, John; Kasamon, Yvette L et al. (2017) Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma. Mol Imaging Biol 19:429-436
Welch, Jennifer J G; Schwartz, Cindy L; Higman, Meghan et al. (2017) Epstein-Barr virus DNA in serum as an early prognostic marker in children and adolescents with Hodgkin lymphoma. Blood Adv 1:681-684
Kanakry, Jennifer A; Gocke, Christopher D; Bolaños-Meade, Javier et al. (2015) Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors. Biol Blood Marrow Transplant 21:2115-2122
Glaser, S L; Clarke, C A; Chang, E T et al. (2014) Hodgkin lymphoma incidence in California Hispanics: influence of nativity and tumor Epstein-Barr virus. Cancer Causes Control 25:709-25
Vendrame, Elena; Hussain, Shehnaz K; Breen, Elizabeth Crabb et al. (2014) Serum levels of cytokines and biomarkers for inflammation and immune activation, and HIV-associated non-Hodgkin B-cell lymphoma risk. Cancer Epidemiol Biomarkers Prev 23:343-9
He, Jian; Wu, Jian; Jiao, Yuchen et al. (2013) Limited detection of IgH gene rearrangements in plasma of patients with primary central nervous system lymphoma. J Neurooncol 114:275-9
Kanakry, Jennifer A; Li, Hailun; Gellert, Lan L et al. (2013) Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood 121:3547-53
Kanakry, Jennifer A; Kasamon, Yvette L; Bolaños-Meade, Javier et al. (2013) Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 19:1514-7
Levin, Lynn I; Chang, Ellen T; Ambinder, Richard F et al. (2012) Atypical prediagnosis Epstein-Barr virus serology restricted to EBV-positive Hodgkin lymphoma. Blood 120:3750-5
Shamay, Meir; Hand, Nicholas; Lemas, M Victor et al. (2012) CpG methylation as a tool to characterize cell-free Kaposi sarcoma herpesvirus DNA. J Infect Dis 205:1095-9

Showing the most recent 10 out of 67 publications